233 related articles for article (PubMed ID: 14530303)
21. Prospects for a vaccine against human papillomavirus.
Hines JF; Ghim S; Schlegel R; Jenson AB
Obstet Gynecol; 1995 Nov; 86(5):860-6. PubMed ID: 7566866
[TBL] [Abstract][Full Text] [Related]
22. Papillomavirus virus-like particles as anticancer vaccines.
Da Silva DM; Velders MP; Rudolf MP; Schiller JT; Kast WM
Curr Opin Mol Ther; 1999 Feb; 1(1):82-8. PubMed ID: 11249689
[TBL] [Abstract][Full Text] [Related]
23. The current state of therapeutic and T cell-based vaccines against human papillomaviruses.
Yang A; Farmer E; Lin J; Wu TC; Hung CF
Virus Res; 2017 Mar; 231():148-165. PubMed ID: 27932207
[TBL] [Abstract][Full Text] [Related]
24. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine.
Jochmus I; Schäfer K; Faath S; Müller M; Gissmann L
Arch Med Res; 1999; 30(4):269-74. PubMed ID: 10573627
[TBL] [Abstract][Full Text] [Related]
25. Vaccines against human papillomavirus.
Lin YY; Alphs H; Hung CF; Roden RB; Wu TC
Front Biosci; 2007 Jan; 12():246-64. PubMed ID: 17127297
[TBL] [Abstract][Full Text] [Related]
26. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus.
Braakhuis BJ; Snijders PJ; Keune WJ; Meijer CJ; Ruijter-Schippers HJ; Leemans CR; Brakenhoff RH
J Natl Cancer Inst; 2004 Jul; 96(13):998-1006. PubMed ID: 15240783
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
Villa LL
Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
[TBL] [Abstract][Full Text] [Related]
28. Papillomavirus-like particles for serology and vaccine development.
Kirnbauer R
Intervirology; 1996; 39(1-2):54-61. PubMed ID: 8957670
[TBL] [Abstract][Full Text] [Related]
29. Human papillomavirus vaccines.
Stanley MA
Curr Opin Mol Ther; 2002 Feb; 4(1):15-22. PubMed ID: 11883690
[TBL] [Abstract][Full Text] [Related]
30. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
31. Papillomaviruses: prophylactic vaccine prospects.
Lowy DR; Schiller JT
Biochim Biophys Acta; 1999 Jan; 1423(1):M1-8. PubMed ID: 9989208
[TBL] [Abstract][Full Text] [Related]
32. [Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].
Huang W; Tian HW; Ren J; Fan JT; Zhao L; Bian T; Lu ZH; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):240-3. PubMed ID: 16261206
[TBL] [Abstract][Full Text] [Related]
33. Prevention of carcinoma of cervix with human papillomavirus vaccine.
Gavarasana S; Kalasapudi RS; Rao TD; Thirumala S
Indian J Cancer; 2000; 37(2-3):57-66. PubMed ID: 11876611
[TBL] [Abstract][Full Text] [Related]
34. Emerging human papillomavirus vaccines.
Ma B; Maraj B; Tran NP; Knoff J; Chen A; Alvarez RD; Hung CF; Wu TC
Expert Opin Emerg Drugs; 2012 Dec; 17(4):469-92. PubMed ID: 23163511
[TBL] [Abstract][Full Text] [Related]
35. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck.
Sirianni N; Ha PK; Oelke M; Califano J; Gooding W; Westra W; Whiteside TL; Koch WM; Schneck JP; DeLeo A; Ferris RL
Clin Cancer Res; 2004 Oct; 10(20):6929-37. PubMed ID: 15501971
[TBL] [Abstract][Full Text] [Related]
36. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA.
Rosales R; López-Contreras M; Cortes RR
J Med Virol; 2001 Dec; 65(4):736-44. PubMed ID: 11745939
[TBL] [Abstract][Full Text] [Related]
37. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
Park JS; Oh YK; Kang MJ; Kim CK
J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
[TBL] [Abstract][Full Text] [Related]
38. Toward a human papillomavirus vaccine.
Rowen D; Lacey C
Dermatol Clin; 1998 Oct; 16(4):835-8. PubMed ID: 9891690
[TBL] [Abstract][Full Text] [Related]
39. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
[TBL] [Abstract][Full Text] [Related]
40. A review of human papillomavirus vaccines: from basic science to clinical trials.
Berry JM; Palefsky JM
Front Biosci; 2003 May; 8():s333-45. PubMed ID: 12700045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
